Regarding this, miR-29 has been reported to contrast HCC progression via specifically targeting and downregulating the Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) and Vascular Endothelial Growth Factor A (VEGFA), as well as anti-apoptotic proteins such as B-cell lymphoma 2 (BCL2) [16,17,18]. This evidence concerns the gene BCL2 and hepatocellular carcinoma.